Accuray Ranked 155th Fastest Growing Company in North America on Deloitte's 2009 Technology Fast 500(TM)
"We are honored to be ranked so highly in a high-profile nationwide listing like the Technology Fast 500," said
"Technology Fast 500(TM) recognizes innovative companies that have broken down barriers to success and defied the odds with their remarkable five-year revenue growth," said
For more information on the Technology Fast 500(TM) selection criteria and 2009 wining companies, please visit www.fast500.com
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames. Treatments are completed in five or fewer outpatient visits and patients can typically return to normal activities immediately following treatment.
About
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, as to system utilization, clinical studies, patient and clinician acceptance and performance of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: clinical results, commercialization of products; market acceptance of products; competing products; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year and our other filings with the
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869
SOURCE
Stephanie Tomei, Senior Manager, Marketing Communications of Accuray Incorporated, +1-408-789-4234, stomei@accuray.com; or Brianne Donahue of Schwartz Communications, +1-415-817-2545, accuray@schwartz-pr.com, for Accuray Incorporated